PRNewswire/ -- Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, announced the milestone of completing 110 client projects on blood cancer treatments using models from their HuKemia® collection.
Innovative Test That Could Predict Risk of Kidney Failure in Pediatric Type 1 Diabetes Patients Announced at 68th AACC Annual Scientific Meeting
PRNewswire-USNewswire/ -- Researchers have successfully tested a new method for the early diagnosis in children and teenagers of diabetic nephropathy, a serious complication of diabetes that can increase risk of death. This new method, unveiled today at the 68th AACC Annual Scientific Meeting & Clinical Lab Expo, would help pediatric patients get necessary treatment in a more timely manner.
FDA CONSUMER HEALTH INFORMATION: FDA Researchers Advance Science for Vaccines to Prevent Mumps and Whooping Cough
PRNewswire-USNewswire/ -- In a light-filled lab at the U.S. Food and Drug Administration, a collection of small containers are growing the bacteria that cause whooping cough.In a nearby lab, cultures of the mumps virus also are being grown for studies aimed at improving the effectiveness of the mumps vaccine. This work is being done because reported cases of mumps and whooping cough (also called "pertussis") have risen in recent years, even though many people are vaccinated.
Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to LEE011 (ribociclib), in combination with letrozole, for the treatment of hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. LEE011 is a selective cyclin dependent kinase (CDK4/6) inhibitor.
Piramal Pharma Solutions Expands Capacity for Sterile Manufacturing in Lexington
Piramal Pharma Solutions’ plan focuses on expanding the Lexington site capabilities and capacity for commercial aseptic manufacturing. This will be done by increasing vial filling capability and lyophilisation capacity, as well as upgrades to the associated facilities and utilities. Piramal’s Lexington site has a strong pipeline of products which are expected to be commercialized in next 3 to 5 years.
RESEARCH TRIANGLE PARK, N.C. & MINNEAPOLIS--(BUSINESS WIRE)--Quintiles, the world’s largest provider of product development and integrated healthcare services, and DaVita Clinical Research, a wholly-owned subsidiary of DaVita HealthCare Partners Inc., a leader in kidney care, today announced a global strategic alliance. The alliance combines DaVita’s world-class clinical care and expansive footprint of research sites with Quintiles’ industry-leading operational delivery and therapeutic expertise in clinical trials.
Teva Announces Acquisition of Anda Inc.
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that it has entered into a definitive agreement to purchase Allergan’s Anda Inc., the 4th largest distributor of generic pharmaceuticals in the U.S. for 0 million.For more information, visit www.tevapharm.com.
CARPINTERIA, Calif.--(BUSINESS WIRE)--Dako, Agilent Pathology Solutions, a worldwide leader in partnering with pharmaceutical companies to develop immunohistochemical-based diagnostics for cancer therapy, today announced the CE Mark certification for use of a new companion diagnostic assay that can reveal whether a patient with advanced non-small cell lung cancer (NSCLC) is likely to respond to KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy manufactured by Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the U.S. and Canada).
RNewswire/ -- Amgen (NASDAQ:AMGN) and Advaxis, Inc. (NASDAQ:ADXS) today announced a global agreement for the development and commercialization of Advaxis' ADXS-NEO, a novel, preclinical investigational cancer immunotherapy treatment that is designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor. This collaboration brings together Amgen's development expertise in immuno-oncology with Advaxis' MINETM (My Immunotherapy Neo-Epitopes) program, which is uniquely positioned to develop a customized approach to cancer treatment. Under the terms of the agreement, Amgen receives exclusive worldwide rights to develop and commercialize ADXS-NEO. Amgen will make an upfront payment to Advaxis of million and purchase million of Advaxis common stock. Amgen will be fully responsible for funding clinical and commercial activities. Advaxis will lead the clinical development of ADXS-NEO through proof-of-concept, retain manufacturing responsibilities, and receive development, regulatory and sales milestone payments of up to 5 million and potential high single digit to mid-double digit royalty payments based on worldwide sales.
Teva has acquired Allergan's legacy Actavis Global Generics business, including the U.S. and international generic commercial units, third-party supplier Medis, global generic manufacturing operations, and the global generic R&D unit, as well as Allergan's international over-the-counter (OTC) commercial unit (excluding OTC eye care products) and certain established international brands.